Adaeze Onuoha, MD
Neurocritical Care · El Paso, TXNPI 1770723587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by UCB, Inc. at 50.9% of the total. Reporting peaked in 2019 at $590 and has fallen 72.3% since, to $163 in 2025.
Across 60 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$707
- Biogen$367
- Microtransponder, Inc.$163
- Medtronic$60
- Neurelis, Inc.$54
- Amneal Pharmaceuticals LLC$22
- plus $13 from 1 others
Across 2 payments — averaging $17,583 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$35K
What the payments were for
- Food & beverage$1,37499%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 34 | $707 |
| Biogen | 19 | $367 |
| Microtransponder, Inc. | 1 | $163 |
| Medtronic | 1 | $60 |
| Neurelis, Inc. | 2 | $54 |
| Amneal Pharmaceuticals LLC | 2 | $22 |
| EMD Serono, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$124
How this compares
$1,387 in reported general payments places this provider in the 80th percentile of 46 neurocritical care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 16 | $399,123 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $233,598 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $103,778 |
| BriviactBrivaracetam | 36 | $57,703 |
| Emgality PenGalcanezumab-Gnlm | 46 | $57,563 |
| NeuproRotigotine | 29 | $47,118 |
| ValtocoDiazepam | 12 | $33,321 |
| Memantine Hcl | 598 | $24,217 |
| Lacosamide | 105 | $16,140 |
| Nurtec OdtRimegepant Sulfate | 11 | $15,297 |
| RivastigmineRivastigmine Tartrate | 135 | $12,869 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 13 | $8,603 |
| Entacapone | 31 | $8,282 |
| Memantine Hcl ErMemantine Hcl | 52 | $7,446 |
| Primidone | 136 | $5,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Neupro | $707 | $104,82065 claims |
| BiogenAvonex (4 Pack) | $367 | $103,77813 claims |
| Neurelis, Inc.Valtoco | $54 | $33,32112 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $22 | $2,44320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 46 neurocritical care providers in Texas.
Other neurocritical care in El Paso
- Faheem SheriffEl Paso$12K
- Salvador Cruz-FloresEl Paso$858
- Paisith PiriyawatEl Paso$392
- Mohammad IbrahimEl Paso$213
- Ali SeifiSan Antonio$58K
- Ashutosh MahapatraHouston$27K
- Ritvij BowryHouston$11K
- Huimahn ChoiHouston$2K
- Claudia PerezFort Worth$2K
- Muhammad Ubaid HafeezHouston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.